PQX1 Stock Overview
Provides solutions and products in the areas of drug discovery and development, analytical testing, and water and environmental testing. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
No risks detected for PQX1 from our risk checks.
Biotage AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 13.00 |
| 52 Week High | SEK 17.33 |
| 52 Week Low | SEK 10.16 |
| Beta | 0.91 |
| 11 Month Change | -17.41% |
| 3 Month Change | -23.80% |
| 1 Year Change | 19.60% |
| 33 Year Change | -48.78% |
| 5 Year Change | 11.49% |
| Change since IPO | 1,733.57% |
Recent News & Updates
Recent updates
Shareholder Returns
| PQX1 | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | -4.0% | -6.1% | -1.3% |
| 1Y | 19.6% | 2.0% | 7.4% |
Return vs Industry: PQX1 exceeded the German Life Sciences industry which returned 2% over the past year.
Return vs Market: PQX1 exceeded the German Market which returned 7.4% over the past year.
Price Volatility
| PQX1 volatility | |
|---|---|
| PQX1 Average Weekly Movement | 5.0% |
| Life Sciences Industry Average Movement | 6.1% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: PQX1 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: PQX1's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1969 | 675 | Frederic Vanderhaegen | www.biotage.com |
Biotage AB (publ) provides solutions and products in the areas of drug discovery and development, analytical testing, and water and environmental testing. The company offers organic and peptide synthesis solutions; flash chromotherapy, evaporation, and work-up products; flash systems; sample preparation products; plasmid purification solutions; oligo synthesis solutions; and metal scavengers and reagents, as well as accessories and spare parts. It also provides sample preparation solutions in the clinical and bioanalytical, forensic and toxicology, doping control animal and human, environment, and food and agriculture areas, as well as consumables and systems; protein purification solutions, including antibody and tagged proteins purification, automation systems, and custom packing service, as well as ion exchange, reversed phase, normal phase, and gel filtration PhyTip columns.
Biotage AB (publ) Fundamentals Summary
| PQX1 fundamental statistics | |
|---|---|
| Market cap | €1.08b |
| Earnings (TTM) | €22.35m |
| Revenue (TTM) | €184.09m |
48.3x
P/E Ratio5.9x
P/S RatioIs PQX1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PQX1 income statement (TTM) | |
|---|---|
| Revenue | SEK 2.12b |
| Cost of Revenue | SEK 794.00m |
| Gross Profit | SEK 1.32b |
| Other Expenses | SEK 1.07b |
| Earnings | SEK 257.00m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 19, 2025
| Earnings per share (EPS) | 3.21 |
| Gross Margin | 62.49% |
| Net Profit Margin | 12.14% |
| Debt/Equity Ratio | 3.9% |
How did PQX1 perform over the long term?
See historical performance and comparison